Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Open Label, Controlled Phase II Study to Evaluate Safety, Tolerability and Immunogenicity After Two Different 13-Valent Pneumococcal Conjugate Vaccine Formulations in Elderly Subjects Aged 65 Years and Older Who Are Naive to Previous 23vPS Immunization

NCT00269672 is registered in ClinicalTrials.gov with Wyeth is now a wholly owned subsidiary of Pfizer as lead sponsor.

NCT NCT00269672
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00269672 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Open Label, Controlled Phase II Study to Evaluate Safety, Tolerability and Immunogenicity After Two Different 13-Valent Pneumococcal Conjugate Vaccine Formulations in Elderly Subjects Aged 65 Years and Older Who Are Naive to Previous 23vPS Immunization
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Phase
Phase 2
Overall status
Completed
Start date
September 30, 2005
Completion date
February 28, 2007
Enrollment
915 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

vaccines, pneumococcal conjugate vaccine